Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan

This article was originally published in PharmAsia News

You may also be interested in...



China’s Environmental Regs Put More Pressure On Pharma

As part of China’s five-year plan, environmental restrictions will increasingly get more attention, but punishments for lax companies will likely be tougher in urban areas where public awareness is greater.

As China Turns To Innovation, Quintiles Goes Local To Woo Chinese Customers

As China Turns To Innovation, Quintiles Goes Local To Woo Chinese Customers

Unlike Quintile’s current offices in Beijing and Shanghai, newly launched Kun Tuo will focus solely on Chinese biopharma customers, offering them custom-tailored solutions at a competitive price point.

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel